Connecticut Zantac Cancer Lawsuit Attorney
What You Need to Know About Ongoing Ranitidine Litigation
In April 2020, the Food and Drug Administration (FDA)
issued a recall of all ranitidine medications and requested manufacturers to withdraw these products from shelves. Ranitidine
is a common ingredient in antiacids, but a recent investigation revealed
that it contains a probable carcinogen called N-Nitrosodimethylamine (NDMA).
According to the FDA’s recall, the level of NDMA in ranitidine-containing
products, such as Zantac, can increase over time and/or when products
are stored at temperatures above room level. As a result, countless consumers
were likely put at risk of consuming dangerous levels of NDMA, which can
lead to numerous forms of cancer.
If you or a loved one took Zantac or a similar ranitidine medication over
a prolonged period of time and later developed cancer, you could be entitled
to take part in ongoing litigation. Our Connecticut Zantac cancer lawsuit
attorneys at RisCassi & Davis, P.C. are currently taking cases involving
patients who took ranitidine medication, leading to cancer. We encourage
you to reach out to us today for a free initial consultation with a member
of our team.
Call RisCassi & Davis, P.C. at
(860) 245-2412 or
contact us online to request a free, no-obligation consultation. We do not charge attorneys’
fees unless we win your case.
What Is Ranitidine & How Is It Dangerous?
Ranitidine is a type of drug known as a histamine-2 (H-2) blocker. It helps
reduce the amount of acid produces by the stomach and, therefore, serves
as an effective medication to help treat and prevent heartburn, gastroesophageal
reflux disease (GERD), and stomach/intestinal ulcers.
While ranitidine itself is not necessarily dangerous, many ranitidine medications
contain an impurity called N-Nitrosodimethylamine, or NDMA. NDMA is a
naturally occurring substance that can also be produced as a result of
various industrial processes. Because ranitidine contains both nitrite
and dimethylamine, the two elements that form NDMA, it has a high risk
of naturally creating NDMA over time or when stored at high temperatures.
Additionally, recent studies have shown that conditions in the human digestive
system can also lead to the formation of NDMA in ranitidine once ingested.
This can have numerous negative health consequences for individuals who
take Zantac and other ranitidine products; namely, they can develop cancer.
What Types of Cancer Does Zantac Cause?
NDMA has been used in labs to create cancer in rats. It is indisputably
a carcinogen, meaning it can potentially cause cancer in humans, as well.
Zantac and other ranitidine medications have been linked to several forms
of cancer, including but not limited to:
- Colorectal cancer
- Stomach cancer
- Intestinal cancer
- Esophageal cancer
- Liver cancer
- Bladder cancer
- Breast cancer
- Pancreatic cancer
- Prostate cancer
- Throat cancer
- Nasal cancer
- Thyroid cancer
- Ovarian cancer
If you were diagnosed with cancer of if someone you love died from cancer
after taking Zantac, you could be entitled to bring a
defective drug claim and recover compensation for your damages under Connecticut’s
product liability laws.
Choose a Trusted & Respected Legal Team
Zantac cancer lawsuits typically have a number of complex challenges. Most
notably, you will need to prove that your cancer resulted from taking
ranitidine medication and not due to outside factors. This can be incredibly
difficult to do without the assistance of a skilled legal team with access
to essential resources.
At RisCassi & Davis, P.C., we work with a team of medical experts and
specialists to build strong, powerful cases for our clients. We are nationally
recognized for our commitment to personalized client representation, aggressive
advocacy, and ethics. We have successfully secured tens of millions of
dollars for our clients in all types of complex
personal injury and
wrongful death claims, and we are ready to fight for you.
To learn more, contact our Connecticut Zantac lawsuit lawyers at
(860) 245-2412 for a free consultation.